MIDA Teams Up With UNMC To Further Promote Investments In R&D

The Malaysian Investment Development Authority (MIDA) has partnered with Nottingham MyResearch Sdn Bhd to organise an outreach programme to further promote the importance of investing in research and development (R&D).

Nottingham MyResearch is R&D status company approved by MIDA and is a fully-owned subsidiary of The University of Nottingham in Malaysia (UNMC).

In a statement Wednesday, MIDA said as the government's principal agency to spearhead the national investment agenda, it has been promoting investments in R&D spending for many years.

Its Second Deputy Chief Executive, N. Rajendran said MIDA wanted to develop strong R&D linkages between the industry and tertiary and research institutions by encouraging and nurturing partnership.

He said such collaborations would lead to higher research value integration that would be translated into commercialisation and drive the growth of companies and the country.

Rajendran said MIDA's R&D incentives programmes could be enjoyed by any investors who want to set up research as a service or have an R&D office within the company.

To date, MIDA said it has approved 150 R&D projects comprising 68 Contract R&D, 44 in-house R&D and 26 R&D companies with total investments of RM2.21 billion and expected to create about 5,000 employment opportunities.

These projects were mainly in healthcare, biofuel, machinery, electrical and electronics, automotive, mining, energy, medical devices, palm oil, agriculture and food production industries, it added.

Meanwhile, Vice Provost at UNMC and Chief Executive Officer of MyResearch, Professor Graham Kendall said the company provided a tax efficient way for companies to invest in R&D.

"We have world experts in many areas, and companies are able to benefit from our expertise and knowledge," he said.

Source : http://www.bernama.com/bernama/v7/bu/newsbusiness.php?id=1067664

Belgium eyes Malaysia for Manufacturing, R&D and Distribution

The visit by a 300-strong Belgian economic delegation to Malaysia from November 22-26 is geared towards exploring opportunities for establishing manufacturing, research and development (R&D), and distribution operations in the country. The economic delegation is being led by Belgium's Princess Astrid.
Jeroen Direkx, managing director (derivatives) of Oleon NV, a leading Belgian company told Bernama that his organisation had been operating in Malaysia for a long time. The company converts vegetable oils into fatty acids and then into ethers. Its biggest market is the lubricant sector.
"We are also active in oil-field chemicals and collaborate with Petronas. Oleon is also active in other applications such as the beauty industry and food additives," he added.
He said Oleon was taking its Malaysian presence to the next level by setting up a R&D centre with an investment of between 4.5 million to five million euros (RM18.8-21 million).
"We are keen to peg down our costs by setting up a R&D centre in Malaysia where it is cost-efficient. Asia is also a fast-growing market, particularly in the applications sector. The cosmetics industry, for example, varies from country to country, depending on consumer tastes. Many of our Asian customers can be served from our Malaysian and Asean operations," explained Direkx, who is also headed for Malaysia. 
The proposed R&D centre is projected to be a 'satellite' to the company's Novance Innovation Centre in France, which assumes a crucial role for the French Group Sofiprotel, that owns Oleon.
Another company in the delegation is Lhoist, which was given a manufacturing licence by Malaysia in 2007 to produce calcium carbonate quicklime, slaked lime and hydrated lime.
Lhoist was also given approval in 2013 to set up a laboratory, a regional lime-application development centre in Perak. A toxic-waste purification plant is also planned in the Klang Valley.
Belgium is also looking at cooperation in the halal food industry and will seek partnerships with Malaysian companies. Belgium has developed a halal industry to cater to the needs of its Muslim population. Belgian companies are reportedly interested in collaborating with the Halal Development Corporation for this purpose.
Besides the corporate representatives, the delegation includes Didier Reynders, the Deputy Prime Minister and Minister of Foreign and European Affairs, as well as Pieter De Crem, Belgium's Secretary of State for Foreign Trade. – Bernama, November 16, 2014.
Source: http://www.themalaysianinsider.com/business/article/belgium-eyes-malaysia-for-manufacturing-rd-and-distribution#sthash.L1ZxOaEN.dpuf

Malaysian Industry-Government Group for High Technology (MIGHT) is working to collaborate with both the United Kingdom (UK) and Japan in financing projects related to science, technology and innovation (STI) in Malaysia

The Malaysian Industry-Government Group for High Technology (Might) is working with the United Kingdom (UK) and Japan to finance science, technology and innovation (STI) projects in Malaysia.

Might Joint-Chairman Prof Tan Sri Zakri Abdul Hamid said the Malaysian government had been working with the British government to set up the Ungku Amar Newton Fund to enhance research and development (R&D) in the local STI industry.

"The British government will allocate four million pounds a year, for five years, into the fund, which will be matched equally by us," he told a press conference after the company's annual general meeting here Friday.

Zakri, who is also the Science Advisor to the Prime Minister, said a memorandum of understanding for the collaboration between Malaysia and the UK would be signed soon, adding that the four million pounds needed to be spent by March 2015.

He noted that the priority areas that the R&D would focus on were the impact of climate change on areas such as water, energy, health and food security.

Meanwhile, on its role in technology nurturing, Might Technology Nurturing (MTN) has signed a heads of agreement with Japan-based Asian Energy Investment Pte Ltd to create a fund management company called Putra Eco Ventures Inc in September last year.

Might President and Chief Executive Officer Dr Mohd Yusoff Sulaiman said the objective of the fund was to invest in efficient and renewable energy assets and businesses.

"Putra Eco Ventures will kick off with US$10 million, which will be replenished once finished. We will start with Melaka because they have already announced their green action plans for the state.

"The potential targets for funding from Putra Eco Ventures involves a lot of projects like smart grid, energy saving activities and smart buildings," he said.

Mohd Yusoff added the company sought to fund projects which have the potential to give return on investments of 10 per cent or more.

Source: http://www.mightinternational.org.my/newsmaster.cfm?&menuid=5&action=view&retrieveid=145#sthash.Td9Dgmhy.dpuf

APAC bio science generated total revenue crossed $173 billion, recorded 12% growth from year 2012 to 2013

Amidst turmoil in many of the Asia-Pacific markets in the past year with general economic slowdown and regulatory and quality issues, the regional bioscience industry had done well in 2013. The 7th annual BioSpectrum Asia-Pacific Bioscience Survey indicates that the industry grew by 12 percent in 2013, compared to 11 percent in 2012. The total revenues crossed $173 billion compared to $154 billion in 2012.

Over 300 publicly listed bioscience companies in the region are the main engines of growth for the APAC industry. Collectively, these companies crossed the $100 billion mark for the first time. Privately held companies, mostly in India and China, accounted for more than 40 percent of the industry's revenue.

Within the region, the performance of various national markets varied wildly. While the industry in China grew by 22 percent in 2013, India's industry recorded an abysmal 3 percent growth only. In terms of growth, Singapore was a big winner with the national bioscience industry on a booster dose with 48 percent growth in 2013. The pharma manufacturers in Singapore had their best year in the past decade, thanks to big orders from the region for many of the locally-made products.

China continued the trend of hosting the largest segment of bioscience industry in the region, followed by India. There are nearly 100 publicly listed bioscience companies in China and their revenue crossed the $50 billion mark for the first time. India's companies are second to China but their combined revenue was just half of that of China, accounting for about $26 billion. In fact, the $25.8 billion revenue of government-controlled, Sinopharm, the No. 1 bioscience company in APAC, is almost equivalent to the combined revenue of all the publicly listed pharma companies in India. The wide gap between the No 1 and No 2 bioscience markets has remained more or less the same for the past five years.

Source: http://www.biospectrumasia.com/biospectrum/opinion/215495/-growth-pushes-apac-bioscience-usd173-bn